Meta-analysis of 68,653 patients found that GLP-1 receptor agonists reduced heart failure hospitalizations and cardiovascular death only in patients without a history of heart failure, but reduced ischemic events (MACE) regardless of HF history.
HR 0.79 vs 1.00 for HF hospitalizationGLP-1 drugs reduced HF hospitalization risk in patients without HF but not in those with existing HF
What the researchers found
GLP-1 RAs reduced HF hospitalization (HR 0.79) and CV death (HR 0.81) only in patients without HF history, while reducing MACE equally regardless of HF history (HR 0.86 no HF, 0.83 with HF).
Why it matters
This clarifies a crucial clinical question: GLP-1 drugs prevent heart failure but may not treat it. Clinicians should use GLP-1RAs early in high-risk patients to prevent HF, while recognizing these drugs may not reduce HF-specific events in patients who already have established heart failure.
The numbers in context
Meta-analysis of all randomized placebo-controlled GLP-1RA trials with CV outcomes reported; stratified by HF history vs. no HF history.
How the study worked
Systematic review and meta-analysis of 10 randomized, placebo-controlled GLP-1RA trials (68,653 patients), stratified by heart failure history. Random-effects model. PROSPERO-registered (CRD42022371264). Primary outcome: HF hospitalizations.
Who was studied
Diabetic patients with and without prior heart failure history across GLP-1RA trials
What this study cannot tell us
Subgroup analysis across trials — individual trials were not powered for HF subgroup comparisons. Different GLP-1RAs pooled together. HF definitions may vary across trials. Cannot distinguish between HFpEF and HFrEF in most trials. Follow-up durations varied.
How to read the evidence
Strong evidence — large meta-analysis of 10 randomized controlled trials with 68,653 patients. Subgroup analysis across trials is a limitation, but the signal is consistent.
When this study was published
Published in 2024. Incorporates the most comprehensive trial data on GLP-1 drugs and heart failure outcomes.
The bigger picture
This meta-analysis reshapes the narrative around GLP-1 drugs and heart failure. Rather than being broadly cardioprotective, their benefit appears to be primarily preventive — protecting hearts that haven't yet failed. This has major implications for treatment timing and patient selection.
Questions still open
- Why do GLP-1 drugs prevent but not treat heart failure?
- Should GLP-1 drugs be prioritized earlier in diabetic patients at HF risk rather than waiting for HF to develop?
- Does the STEP-HFpEF trial (semaglutide 2.4 mg for obesity-HFpEF) contradict or complement these findings?
Common questions
Do GLP-1 drugs like Ozempic help with heart failure?
Should I start a GLP-1 drug before I develop heart failure?
Read the original research
GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.
Clinical research in cardiology : official journal of the German Cardiac Society, 113(6), 898-909
Citation
Villaschi, Alessandro; Ferrante, Giuseppe; Cannata, Francesco; Pini, Daniela; Pagnesi, Matteo; Corrada, Elena; Reimers, Bernhard; Mehran, Roxana; Federici, Massimo; Savarese, Gianluigi; Metra, Marco; Condorelli, Gianluigi; Stefanini, Giulio G; Chiarito, Mauro. (2024). GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.. Clinical research in cardiology : official journal of the German Cardiac Society, 113(6), 898-909. https://doi.org/10.1007/s00392-023-02362-6